Mirzaee Faezeh, Abbaszade-CheragheAli Ali, Khamoushi Atefeh
Jiroft University of Medical Science, Kerman, Iran.
Tehran University of Medical Science, Tehran, Iran.
Mol Genet Genomics. 2025 Jun 11;300(1):59. doi: 10.1007/s00438-025-02266-2.
High mobility group (HMG) proteins, the second most abundant chromatin proteins after histones, play essential roles in eukaryotic gene regulation. Among these, High Mobility Group Box 3 (HMGB3) is critical for DNA repair and has gained prominence in cancer biology due to its involvement in tumorigenesis and cancer progression. This study explores the cellular and molecular mechanisms underlying HMGB3's oncogenic functions, with a focus on its potential as a prognostic biomarker and therapeutic target. We highlight that HMGB3 is frequently overexpressed in tumor tissues and discuss its association with poor clinical outcomes. Furthermore, we examine the ceRNA network and other regulatory pathways influencing HMGB3 expression, emphasizing their implications for RNA-based therapies. By comprehensively reviewing HMGB3's role across multiple cancer types, this work provides insights into novel strategies for targeting HMGB3 to improve cancer treatment efficacy. Our findings underscore the therapeutic potential of modulating HMGB3 expression and pave the way for future research into precision oncology approaches.
高迁移率族（HMG）蛋白是仅次于组蛋白的第二丰富的染色质蛋白，在真核基因调控中发挥着重要作用。其中，高迁移率族框3（HMGB3）对DNA修复至关重要，并且由于其参与肿瘤发生和癌症进展，在癌症生物学中受到了关注。本研究探讨了HMGB3致癌功能的细胞和分子机制，重点关注其作为预后生物标志物和治疗靶点的潜力。我们强调HMGB3在肿瘤组织中经常过度表达，并讨论其与不良临床结果的关联。此外，我们研究了影响HMGB3表达的ceRNA网络和其他调控途径，强调了它们对基于RNA的治疗的影响。通过全面综述HMGB3在多种癌症类型中的作用，这项工作为靶向HMGB3以提高癌症治疗疗效的新策略提供了见解。我们的研究结果强调了调节HMGB3表达的治疗潜力，并为未来精准肿瘤学方法的研究铺平了道路。
